Acute Monocytic Leukemia

This is another type of acute leukemia that affects the monocytic cells, a type of white blood cell. In this condition, a large percentage of the white blood cells are of monocytic origin. It's a serious form of leukemia that can quickly affect the body.

Condition

What people with Acute Monocytic Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Cytarabine for Acute Monocytic Leukemia?

NameHow it went

About Acute Monocytic Leukemia

What It Is

Acute monocytic leukemia is a subtype of acute myeloid leukemia (AML), a fast-growing cancer that starts in the bone marrow, where blood cells are made. In this subtype, most of the leukemia cells are immature forms of monocytes, a type of white blood cell. These cells multiply without maturing into working blood cells, and they crowd out the healthy cells the marrow should be making. The result is usually too few red blood cells (causing tiredness and breathlessness), too few normal white blood cells (raising the risk of infection) and too few platelets (causing easy bruising and bleeding). "Acute" means the disease usually worsens quickly without treatment. Monocytic leukemia cells have a particular tendency to move out of the blood into body tissues. Some people first notice swollen, sore or bleeding gums, or lumps and spots on the skin that can look like an ordinary rash. Less often the cells reach the brain and spinal cord. Acute monocytic leukemia accounts for roughly 5 to 10 percent of AML. Doctors once called it AML-M5; current classifications group AML mainly by the genetic changes in the leukemia cells, and use the monocytic label when no defining genetic change is found.

Causes & Risk Factors

Like other forms of AML, acute monocytic leukemia begins when bone marrow cells acquire changes in their DNA that let them grow out of control. In most people, why those changes happened cannot be identified, and they are not caused by anything the person did. Factors that raise the risk of AML in general include older age, being male, smoking, previous chemotherapy or radiation therapy, exposure to the industrial chemical benzene, and an earlier blood disorder such as myelodysplastic syndrome (a condition in which the marrow makes faulty blood cells). One genetic change in the leukemia cells, a rearrangement of the KMT2A gene on chromosome 11, is often found with monocytic features. It is more common in children than adults, appears often in infants with AML, and is also seen in leukemia that develops after earlier treatment with certain chemotherapy drugs. This rearrangement arises in the leukemia cells themselves; it is not usually inherited or passed to children.

How It's Diagnosed

A complete blood count, which measures red cells, white cells and platelets, is often the first clue. It may show low counts, a very high white cell count, or immature cells called blasts in the blood. A bone marrow aspiration and biopsy, in which a needle removes a small sample of liquid marrow and bone, usually from the back of the hip, confirms the diagnosis. AML is generally diagnosed when blasts make up 20 percent or more of the cells in the blood or marrow, though certain genetic changes establish AML even below that level. Specialized laboratory tests then identify the cells as monocytic, using stains and flow cytometry, a test that reads the protein markers on each cell's surface. Chromosome and gene tests are essential because results such as KMT2A rearrangement or mutations in genes like NPM1 or FLT3 shape both the outlook and the choice of treatment. In studies, these genetic features predicted outcomes better than the monocytic appearance alone. A biopsy of swollen gums or a skin lump can show leukemia there, and a lumbar puncture (spinal tap) may be done to look for leukemia cells in the fluid around the brain and spinal cord.

Treatment Options

Treatment usually starts soon after diagnosis and follows the same principles as other AML. For people healthy enough for intensive treatment, the first phase, called induction, aims for remission, meaning no detectable leukemia in the blood or marrow and recovery of normal counts. A common regimen combines cytarabine with an anthracycline such as daunorubicin or idarubicin (often called "7 + 3" for the days each drug is given). A targeted drug may be added when tests find a matching feature, such as a FLT3 mutation. Induction also wipes out healthy marrow for a few weeks, so it is given in the hospital with transfusions and medicines to prevent or treat infection. The second phase, consolidation, tries to destroy remaining leukemia cells and prevent relapse. It may be several cycles of high-dose cytarabine or an allogeneic stem cell transplant, which replaces the marrow with a donor's blood-forming cells. A transplant lowers the chance of the leukemia returning more than chemotherapy alone, but it carries a higher risk of serious complications, so the choice depends on the leukemia's genetic risk, age, overall health and personal priorities. Leukemia in the brain or spinal cord is treated by giving chemotherapy directly into the spinal fluid. For older adults or people who cannot tolerate intensive chemotherapy, a common option is azacitidine or decitabine (lower-intensity chemotherapy drugs) combined with venetoclax (Venclexta), a pill that blocks a protein leukemia cells use to survive. Several studies found that leukemia with monocytic features responds somewhat less well to venetoclax combinations, although the leukemia's gene mutations seem to matter more than its monocytic appearance. Clinical trials testing newer approaches are often worth asking about.

What to Expect

Intensive treatment is demanding. Induction usually means several weeks in the hospital while blood counts are very low, followed by months of consolidation, frequent blood tests, transfusions and repeated bone marrow tests to check whether remission has been reached and is holding. Fatigue, infections and time away from work or school are common during this period. Lower-intensity treatment is usually given as an outpatient in repeated cycles for as long as it keeps the leukemia controlled, though early cycles can still bring low counts and hospital stays. The outlook varies widely. Among adults with AML overall, about 60 to 70 percent reach complete remission with intensive induction, and a little over a quarter remain free of leukemia three or more years later and may be cured. Older trial data suggest acute monocytic leukemia does about as well with intensive chemotherapy as other AML subtypes. Age, general health and the leukemia's genetic features shape an individual's chances far more than the subtype name. Relapse is a real possibility, especially in the first few years, so regular follow-up continues after treatment ends, and people who have had a transplant need long-term monitoring for its late effects.

When to Seek Help

See a clinician promptly, within days rather than weeks, for unexplained tiredness with paleness or breathlessness, easy bruising or tiny red spots on the skin, swollen or bleeding gums, new skin lumps, repeated infections or bone pain, particularly when several occur together. During treatment, call your care team right away for a fever of 100.5°F (38°C) or higher, shaking chills, or bleeding that will not stop, because infections and bleeding can become life threatening quickly when counts are low. Sudden severe headache, weakness on one side of the body, slurred speech, confusion, sudden trouble breathing or sudden vision loss need emergency care immediately; very high leukemia cell counts can block small blood vessels and cause these stroke-like symptoms.

Questions to Ask Your Doctor

  1. 1.What did the genetic tests show about my leukemia, and how do those results change my outlook and treatment?
  2. 2.Am I a candidate for intensive chemotherapy or a stem cell transplant, and what are the realistic benefits and risks of each for me?
  3. 3.If you recommend a venetoclax combination, how might the monocytic features of my leukemia affect how well it works?
  4. 4.How much time in the hospital should I expect, and what precautions will I need while my blood counts are low?
  5. 5.Is there a clinical trial that fits my situation?

Last reviewed • Oct 2026

Educational content, not medical advice.